Trial Profile
A Phase II Trial of the Efficacy and Safety of Tocilizumab for Treatment of Inflammation in the Renal Allograft
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Mycophenolate mofetil; Prednisone
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 17 Dec 2020 Results assessing whether Interleukin-6 Blockade with Tocilizumab Increases Tregs and Reduces T Effector Cytokines in Renal Graft Inflammation, published in the American Journal of Transplantation
- 16 Mar 2020 Status changed from active, no longer recruiting to completed.
- 10 Oct 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2018.